Will Perspective Therapeutics stock go up?

According to Danelfin AI, Perspective Therapeutics has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (52.00%) is +1.19% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Perspective Therapeutics stock?

The Perspective Therapeutics target price is $14.6 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Perspective Therapeutics stock right now?

Perspective Therapeutics has today a Hold rating (AI Score 5/10), according to Danelfin AI. Its probability of beating the market in 3 months (52.00%) is +1.19% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Perspective Therapeutics stock is a good buy .

Is Perspective Therapeutics undervalued right now?

Based on analysts, the average price target upside for Perspective Therapeutics is +320.72% (1Y). According to Danelfin AI, Perspective Therapeutics has today an AI Score of 5/10 (Hold Rating).

What was the price range of Perspective Therapeutics stock over the past 12 months?

The Perspective Therapeutics stock price range over the past 12 months has been $2.05 - $5.65.

What is going on with Perspective Therapeutics stock in the last 3 months?

The Perspective Therapeutics stock performance in the last quarter has been -16.78%.

Does Perspective Therapeutics offer dividend payments?

No, Perspective Therapeutics does not currently pay dividends.

What is the current market capitalization of Perspective Therapeutics?

Perspective Therapeutics's market cap is $394.6M, as of 2026-07-02 08:00.

When is the next CATX earnings report date?

CATX will publish its next earnings report on 2026-05-11.

Perspective Therapeutics Inc (CATX) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

CATX AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Perspective Therapeutics Inc today receives an AI Score of 5/10, which translates to a Hold rating. The stock has a 52% probability of outperforming the market in the next 3 months, which is 1% higher than the average probability of any stock (51%). This marginal edge is driven by several factors. Positively, the long tail of fundamental signals not detailed here provides the largest boost (+2.71%), while its Biotechnology industry classification also adds to the probability (+1.08%). However, these are offset by detractors: despite being in the top 10% for Gross Margin (100%), this metric actually reduces the probability (-0.95%), and a high Sloan Ratio in the top 10% similarly weighs it down (-0.94%), suggesting earnings quality concerns. Contextual data highlights the stock's mixed profile. While its Operating Cash Flow is in the bottom 10%, this surprisingly contributes positively (+1.19%), and its Tangible Shareholders' Equity ranking in the top 40% offers a slight boost (+0.38%). Conversely, a Fear & Greed Index reading of 31 (indicating fear) detracts (-0.60%), and its high Beta of 1.79, placing it in the top 20% for volatility, is a negative factor (-0.38%). The combination of strong profitability metrics that are paradoxically negative signals, coupled with weak cash flow and high volatility, creates a neutral overall picture, justifying the Hold rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Valuation+2.78%
How the stock is priced relative to its fundamentals
Sentiment+0.91%
How analysts and the market view the stock
Earnings Quality+0.25%
Stability and reliability of reported earnings
Size & Liquidity+0.21%
Company size and trading liquidity

Momentum-1.27%
Direction and strength of recent price movements
Profitability-1.09%
Profitability and operating efficiency metrics
Volatility-0.38%
How much the stock price tends to fluctuate
Financial Strength-0.21%
Balance sheet strength and financial resilience

CATX probability advantage of beating the market (3M):

+1.19%

AI Score

Hold

Perspective Therapeutics (CATX) has an AI Score of 5/10 (Hold) because, according to an overall analysis, it has a probability advantage of +1.19% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of CATX (52.00%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
CATX probability advantage of beating the market (3M)+1.19%
CATX probability of beating the market (3M)52.00%

CATX probability advantage of beating the market (3M): +1.19%

The AI-powered overall analysis of Perspective Therapeutics (CATX) is based on the 29 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of CATX:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+2.71%
Fundamental	Operating Cash Flow (Qtr Discrete)	-31.47	N/A	+1.19%
Sentiment	Industry (GICS)	Biotechnology	N/A	+1.08%
Fundamental	Gross Margin	100		-0.95%
Fundamental	Sloan Ratio	0.28		-0.94%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.60%
Technical	Chart Pattern (180d)	figure_44	N/A	-0.59%
Technical	Chart Pattern (120d)	figure_43	N/A	+0.46%
Technical	Performance (YTD)	0.26%		-0.46%
Fundamental	Tangible Shareholders' Equity	307.44		+0.38%
Technical	Upgrade to unlock			-0.38%
Technical	Upgrade to unlock			-0.35%
Sentiment	Upgrade to unlock			+0.33%
Fundamental	Upgrade to unlock			-0.31%
Fundamental	Upgrade to unlock			-0.31%

Rest of Alpha Signals: -0.07%

CATX probability advantage of beating the market (3M)Total:+1.19%
CATX AI Score

Significant changes Vs previous day

CATX Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$3.47
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

CATX Proven Hold Signal & Price Forecast

This is the price chart for CATX from January 2, 2026 until today. The chart indicates, in yellow, the 68 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

CATX Average Past Performance & Win Rate

Three months after its 1310 Hold signals since July 2026, CATX had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

1310 Past CATX Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+26.43%
Average Alpha				+14.01%
Win Rate (% Positive Perf.)				53.05%
% Positive Alpha				39.83%

CATX Frequently Asked Questions

Will Perspective Therapeutics stock go up?
According to Danelfin AI, Perspective Therapeutics has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (52.00%) is +1.19% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Perspective Therapeutics stock?
Is it a good time to buy, sell, or hold Perspective Therapeutics stock right now?
Is Perspective Therapeutics undervalued right now?
What was the price range of Perspective Therapeutics stock over the past 12 months?
What is going on with Perspective Therapeutics stock in the last 3 months?
Does Perspective Therapeutics offer dividend payments?
What is the current market capitalization of Perspective Therapeutics?
When is the next CATX earnings report date?

Perspective Therapeutics Inc Company Profile

Perspective Therapeutics, Inc., along with its subsidiary firms, is a pioneer in the domain of precision-targeted alpha oncological therapies (TAT) which serves a myriad of cancer patients, from diverse tumor variations to metastatic ailments. The company excels at discerning, conceiving, and advancing its flagship program candidates, including VMT-a-NET. Currently undergoing Phase 1/2a clinical trials, VMT-a-NET targets patients battling unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressive tumors that haven't been treated with peptide-diagnosed radiopharmaceutical therapy like Lutathera; a beta-emission treatment.

An additional notable candidate - VMT01 - is being trialed in Phase 1/2a for treating patients confronted by progressive melanocortin 1 receptor (MC1R) metastatic melanoma at second-line treatment or beyond. In the realm of research partnerships, Perspective Therapeutics has joined hands with Bristol Myers Squibb for clinical trial collaboration. The alliance aims for investigating the safety and tolerability facets of combining [212Pb] VMT01 with Nivolumab for patients having histologically affirmed melanoma coupled with positive MC1R imaging scans.

Before adopting its current banner in February 2022, the company operated under the name Isoray, Inc. Perspective Therapeutics was born in 1998 and has situated its primary operations base in Seattle, Washington.

Sector:
Country:United States
Industry:
Address:2401 Elliott Avenue, Suite 320, Seattle
Employees:163
Website:perspectivetherapeutics.com

Pros

Proprietary intellectual property in targeted radiopharmaceuticals

High barriers to entry in radiopharmaceutical production

Growing demand for precision oncology treatments

Potential for premium pricing on novel therapies

High switching costs for established treatment protocols

Cons

Extremely high capital intensity for drug development

Binary outcomes from clinical trial failures

Complex and regulated radioisotope supply chain dependency

Intense competition from alternative cancer therapies

Reimbursement uncertainty and payer pricing pressure

Company	AI Score	Compare
RADXRadiopharm Theranostics Ltd
IPSCCentury Therapeutics Inc
TNGXTango Therapeutics Inc
PTCTPTC Therapeutics Inc
PSTVPlus Therapeutics Inc

Company	AI Score	Compare
RADXRadiopharm Theranostics Ltd
IPSCCentury Therapeutics Inc
TNGXTango Therapeutics Inc
PTCTPTC Therapeutics Inc
PSTVPlus Therapeutics Inc

CATX Stock AI Analysis High Risk